KT

Kader Thiam

Senior Vice President Discovery - Preclinical Models & Services at genOway

Kader Thiam has a background in the biotech industry, with a long tenure at genOway, where they have held various leadership positions. Kader started at genOway in 1999 as a Scientific Sales Manager and later became the Director of Immunology Department and Head of Business Development. In 2005, they were promoted to the role of Director of Transgenic Technologies and Director of Business Development. From 2009 to 2019, Kader served as the Vice President of Transgenic Technologies, spearheading the development and commercialization of product lines in immunology and inflammation. Currently, Kader holds the position of Senior Vice President Discovery - Preclinical Models & Services, a role they have been in since January 2020. Throughout their career, they have been responsible for establishing and managing alliances with top biopharmaceutical companies and leading research institutes. Prior to their time at genOway, Kader worked as a PhD student and post-doc at the Institut Pasteur.

Kader Thiam completed a Master's degree in Immunology and Cell Biology at the University Paris VI, Pierre et Marie Curie, Paris, France in 1994. In 1995, they attended the School of Medicine, University Lille II, School of Pharmacy Montpellier, France, where they received a DEA degree in Immunology and Parasitology.

Location

Lyon, France

Links

Previous companies


Org chart


Teams

This person is not in any teams


Offices


genOway

1 followers

Founded in 1999, genOway is a global biotechnology company dedicated to the development and commercialization of unique, innovative genetically modified mouse, rat and cell line models for fundamental, preclinical and clinical research. Based on its core business and leading expertise in custom-designed models, the company invests in cancer research, with a growing catalog of currently over 30 translational models for immuno-oncology and immunotherapy. genOway holds all relevant licenses on patented technologies used for its model creation, including the exclusive license under Merck’s foundational CRISPR/Cas9 patents portfolio, which enables the company to guarantee its clients FTO, freedom to operate. Headquartered in Lyon, France, genOway serves clients in 380 academic institutions and 170 life sciences companies, including 17 of the top 20 pharma.


Industries

Headquarters

Lyon, France

Employees

51-200

Links